New ELISA assays were developed to measure immunoreactivity for XMRV. Antibody titers were measured in a cohort of prostate cancer cases and cancer free controls from the central United States. No statistically significant differences were observed in immunoreactivity between cases and controls for either the XMRV-env or the XMRV-gag antigen.
- Prostate cancer
- Xenotropic murine leukemia Virus-related virus
ASJC Scopus subject areas
- Molecular Biology
- Cell Biology